Back | Next |
home / stock / epzm / epzm message board
Subject | By | Source | When |
---|---|---|---|
Okay, so 7.50 support back then tells me | JJL | investorshub | 04/13/2022 12:52:27 AM |
I'm 3 grand in @1.53 and holding on | Yordle | investorshub | 02/12/2022 4:27:52 AM |
Is anybody out there still following this ticker? | choo choo trader | investorshub | 02/09/2022 9:57:34 PM |
Hope it does something tomorrow | Txguy_01 | investorshub | 01/24/2020 1:19:16 AM |
You'd think it's a no brainer. Usually stocks | JC$ | investorshub | 01/24/2020 12:34:02 AM |
Where is this one going tomorrow? | Txguy_01 | investorshub | 01/22/2020 8:25:45 PM |
Nice comeback! | HeadHunter | investorshub | 01/06/2020 8:59:57 PM |
3 Healthcare Stocks to Watch With Huge FDA | jonny_red | investorshub | 12/30/2019 4:21:17 PM |
* * $EPZM Video Chart 01-04-2019 * * | ClayTrader | investorshub | 01/04/2019 10:21:36 PM |
7.20 > tutes pounding the table buying those | crudeoil24 | investorshub | 01/04/2019 4:47:39 PM |
7.00 > Epizyme shares are trading higher after | crudeoil24 | investorshub | 01/04/2019 3:55:32 PM |
Upgrade for October 2nd, 2018 | stockguard | investorshub | 09/29/2018 5:07:55 PM |
Epizyme: An Updated Investment Thesis | stockguard | investorshub | 09/27/2018 5:13:35 PM |
Rumors of a buyout with the favorable clinical | floored | investorshub | 06/15/2017 11:44:03 PM |
Nice $EPZM mention here | floWteiuQ | investorshub | 09/15/2016 3:01:30 PM |
Looks pretty good over here, may have to | Yo-Yo | investorshub | 09/13/2016 12:01:19 AM |
You bet your bippy it is! | floWteiuQ | investorshub | 08/13/2016 3:50:21 PM |
Is the Epizyme Dip A Discount Entry Opportunity? | trendmkr | investorshub | 08/09/2016 6:43:08 PM |
$EPZM-Looking to make some traction today.. | BettingAngles | investorshub | 07/18/2016 4:08:47 PM |
$EPZM-Bouncing | BettingAngles | investorshub | 07/15/2016 4:01:02 PM |
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...